Swiss National Bank Buys 296,900 Shares of Pfizer Inc. (PFE)

Swiss National Bank boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,367,689 shares of the biopharmaceutical company’s stock after buying an additional 296,900 shares during the period. Pfizer makes up approximately 0.9% of Swiss National Bank’s holdings, making the stock its 12th largest holding. Swiss National Bank owned approximately 1.40% of Pfizer worth $784,921,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in PFE. Canada Pension Plan Investment Board increased its stake in Pfizer by 249.6% in the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after purchasing an additional 7,649,416 shares during the period. Principal Financial Group Inc. increased its stake in Pfizer by 46.9% in the second quarter. Principal Financial Group Inc. now owns 14,615,268 shares of the biopharmaceutical company’s stock worth $490,927,000 after purchasing an additional 4,664,868 shares during the period. Marshall Wace North America L.P. increased its stake in Pfizer by 142.8% in the second quarter. Marshall Wace North America L.P. now owns 4,229,547 shares of the biopharmaceutical company’s stock worth $143,805,000 after purchasing an additional 2,487,663 shares during the period. Sentry Investments Corp. increased its stake in Pfizer by 375.9% in the second quarter. Sentry Investments Corp. now owns 2,735,100 shares of the biopharmaceutical company’s stock worth $91,872,000 after purchasing an additional 2,160,400 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in Pfizer by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock worth $1,117,696,000 after purchasing an additional 2,013,835 shares during the period. Institutional investors own 69.89% of the company’s stock.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by corporate insiders.

A number of analysts have weighed in on PFE shares. Cowen set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Monday, August 14th. BMO Capital Markets set a $37.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 10th. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday, October 3rd. Finally, Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Buy” and a consensus target price of $38.77.

Pfizer Inc. (PFE) traded down $0.43 on Wednesday, hitting $35.63. The stock had a trading volume of 22,320,600 shares, compared to its average volume of 19,989,418. Pfizer Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $211,960.00, a P/E ratio of 14.42, a price-to-earnings-growth ratio of 2.54 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the prior year, the company earned $0.61 EPS. The business’s revenue was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date was Thursday, November 9th. Pfizer’s payout ratio is currently 78.53%.

TRADEMARK VIOLATION WARNING: This news story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://stocknewstimes.com/2017/12/06/swiss-national-bank-buys-296900-shares-of-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply